Mross K - Ruhr Univ Bochum | 人才画像

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 38 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

D Strumberg, M E Scheulen,B Schultheis, H Richly,A Frost,M Büchert, O Christensen,M Jeffers, R Heinig, O Boix,K Mross

BRITISH JOURNAL OF CANCER（2012）

引用239浏览0WOSNATURE引用

239

Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis

U Fasol,A Frost,M Büchert,J Arends,U Fiedler,D Scharr,J Scheuenpflug,K Mross

Annals of Oncology（2012）

引用90浏览0WOS引用

Phase I Study Of Regorafenib Sequentially Administered With Either Folfox Or Folfiri In Patients With First-/Second-Line Colorectal Cancer

Beate Schultheis,G. Folprecht,J. Kuhlmann,R. Ehrenberg,U. T. Hacker,C. Kohne,Martin Kornacker,O. Boix, T. Lin,J. Krauss,R. Fischer,S. Hamann,

JOURNAL OF CLINICAL ONCOLOGY（2011）

引用8浏览0引用

FOLFOX or FOLFIRI in combination with sequentially administered regorafenib as first- or second-line treatment in patients with colorectal cancer

B Schultheis,G Folprecht, Jan B Kuhlmann,R Ehrenberg,U Hacker,C H Kohne,M Kornacker, O Boix,Tianwei Lin,J Krauss,Roland A Fischer,Susanne Hamann,

ONKOLOGIEno. SUPnan (2011): 188-189

引用23浏览0引用

Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer

Dirk Strumberg,Beate Schultheis, M. E. Scheulen, R. A. Hilger, J. Krauss, N. Marschner,F. Lordick,F. Bach,D. Reuter, L. Edler,K. Mross

Investigational new drugs（2010）

引用85浏览0WOS引用

Phase I Study Of Bay 73-4506, An Inhibitor Of Oncogenic And Angiogenic Kinases, In Patients With Advanced Refractory Colorectal Carcinoma (Crc)

Dirk Strumberg,M E Scheulen,A Frost,Martin Buchert,Olaf Christensen,Andrea Wagner,R Heinig,Ulrike Fasol,K Mross

JOURNAL OF CLINICAL ONCOLOGY（2009）

引用35浏览0引用

Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours

D Strumberg, B Schultheis,I A Adamietz,O Christensen,M Buechert, J Kraetzschmar,P Rajagopalan,M Ludwig,A Frost, S Steinbild, M E Scheulen,K Mross

British Journal of Cancerno. 10 (2008): 1579-1585

引用22浏览0WOSNATURE引用

41 POSTER Clinical and biomarker responses in a phase I study of BAY 57 9352 – a VEGFR-2 inhibitor – administered as continuous dosing in patients with advanced solid tumors

D STRUMBERG,O CHRISTENSEN,R STRECKER,M SCHEULEN,A FROST,P RAJAGOPALAN,D VOLIOTIS,M ZUEHLSDORF,G WENSING,K MROSS

European Journal of Cancer Supplements（2006）

引用0浏览0引用

A Phase I Clinical And Pharmacokinetic Study Of The Camptothecin Glycoconjugate, Bay 38-3441, As A Daily Infusion In Patients With Advanced Solid Tumors

K Mross, H Richly,N Schleucher, S Korfee,M Tewes, Me Scheulen,S Seeber, T Beinert, M Schweigert,U Sauer,C Unger,D Behringer,

Annals of oncology : official journal of the European Society for Medical Oncologyno. 8 (2004): 1284-1294

引用25浏览0WOS引用

557 BBR 3576: phase I dose escalation study in patients with advanced solid tumors (a study with the participation of CESAR-EWIV)

M SCHEULEN,K MROSS, C PESCHEL, C UNGER,H RICHLY,M CAMBONI, P BARBIERI,E VERDI,B VINCENZI,A BERNAREGGI

Ejc Supplements（2003）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn